With 1.21 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.1 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $11.76 whereas the lowest price it dropped to was $8.7. The 52-week range on QNTM shows that it touched its highest point at $38.25 and its lowest point at $2.70 during that stretch. It currently has a 1-year price target of $45.00. Beta for the stock currently stands at 0.19.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of QNTM was up-trending over the past week, with a rise of 80.82%, but this was down by -11.96% over a month. Three-month performance dropped to -33.86% while six-month performance fell -9.30%. The stock gained 210.05% in the past year, while it has gained 110.52% so far this year. A look at the trailing 12-month EPS for QNTM yields -13.03 with Next year EPS estimates of -3.68. For the next quarter, that number is -1.00. This implies an EPS growth rate of 38.19% for this year and 54.62% for next year.
Float and Shares Shorts:
At present, 3.47 million QNTM shares are outstanding with a float of 2.65 million shares on hand for trading. On 2025-11-14, short shares totaled 32912.0, which was 86.0 higher than short shares on 1760486400. In addition to Mr. Zeeshan Saeed as the firm’s Co-Founder, CEO, & Executive Non-Independent Co-Chairman, Mr. Anthony John Durkacz serves as its Co-Founder & Executive Non-Independent Co-Chairman.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-09-30, QNTM reported revenue of $0.0 and operating income of -$4658195.0. The EBITDA in the recently reported quarter was -$4406237.0 and diluted EPS was -$1.25.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With QNTM analysts setting a high price target of 44.9215 and a low target of 44.9215, the average target price over the next 12 months is 44.9215. Based on these targets, QNTM could surge 293.7% to reach the target high and rise by 293.7% to reach the target low. Reaching the average price target will result in a growth of 293.7% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$3.18159 being high and -$3.18159 being low. For QNTM, this leads to a yearly average estimate of -$3.18159.
